15.70

3.03% -0.49

Fulgent Genetics Inc (FLGT)

Overview News Price History Option Chain Financials Discussions Forecast

Fulgent Genetics Inc stock is traded at $15.70, with a volume of 471.57K. It is down -3.03% in the last 24 hours and down -2.91% over the past month. Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.

Previous Close:

$16.19

Open:

$16.01

24h Volume:

471.57K

Relative Volume:

0.76

Market Cap:

$445.89M

Revenue:

$320.35M

Net Income/Loss:

$-75.01M

P/E Ratio:

-6.5545

EPS:

-2.3953

Net Cash Flow:

$-113.17M

1W Performance:

-1.63%

1M Performance:

-2.91%

6M Performance:

-46.05%

1Y Performance:

-21.66%

1-Day Range:

$15.66

$16.10

1-Week Range:

$15.58

$16.37

52-Week Range:

$13.46

$31.04

Fulgent Genetics Inc Stock (FLGT) Company Profile

Name

Fulgent Genetics Inc

Sector

Healthcare (1101)

Industry

Diagnostics & Research (52)

Phone

626-350-0537

Address

4399 SANTA ANITA AVE, EL MONTE

Employee

1,315

Twitter

@FulgentGenetics

Next Earnings Date

2026-05-01

Latest SEC Filings

FLGT's Discussions on Twitter

Compare FLGT vs TMO, DHR, IDXX, WAT, A

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FLGT Fulgent Genetics Inc	15.70	459.81M	320.35M	-75.01M	-113.17M	-2.3953
TMO Thermo Fisher Scientific Inc	438.34	166.56B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	161.91	116.46B	24.78B	3.68B	5.29B	5.1743
IDXX Idexx Laboratories Inc	528.79	42.03B	4.45B	1.10B	1.06B	13.59
WAT Waters Corp	329.22	32.72B	3.77B	449.25M	240.68M	7.8556
A Agilent Technologies Inc	111.70	32.01B	7.07B	1.29B	993.00M	4.5355

Fulgent Genetics Inc Stock (FLGT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-05-25	Upgrade	UBS	Neutral → Buy
Dec-07-23	Initiated	UBS	Neutral
Dec-08-22	Downgrade	Piper Sandler	Overweight → Neutral
Nov-18-22	Initiated	Raymond James	Outperform
Aug-25-22	Initiated	Credit Suisse	Outperform
Feb-04-22	Resumed	Piper Sandler	Overweight
Aug-05-21	Resumed	Credit Suisse	Underperform
Jan-08-21	Downgrade	Credit Suisse	Neutral → Underperform
Nov-24-20	Downgrade	BTIG Research	Buy → Neutral
Aug-20-20	Initiated	Oppenheimer	Outperform
May-29-20	Initiated	BTIG Research	Buy
Nov-05-19	Upgrade	Piper Jaffray	Neutral → Overweight
Mar-01-18	Downgrade	Piper Jaffray	Overweight → Neutral
Nov-07-17	Downgrade	Raymond James	Outperform → Mkt Perform

View All

Fulgent Genetics Inc Stock (FLGT) Latest News

May 17, 2026

Fulgent Genetics (FLGT) price target decreased by 28.85% to 18.87 - MSN

May 17, 2026

May 14, 2026

Fulgent Genetics Shareholders Approve New 2026 Equity Plan - TipRanks

May 14, 2026

Fulgent Genetics (NASDAQ: FLGT) wins stockholder approval for 2026 equity plan - Stock Titan

May 14, 2026

ETFs Investing in Fulgent Genetics, Inc. Stocks - TradingView

May 14, 2026

May 13, 2026

Responsive Playbooks and the FLGT Inflection - Stock Traders Daily

May 13, 2026

May 12, 2026

Fulgent Genetics infertility test panels broaden to cover over 140 genes for females and 160 for males - Traders Union

May 12, 2026

TradingKey - TradingKey

May 12, 2026

May 11, 2026

LA500 2026: Ming Hsieh - Los Angeles Business Journal

May 11, 2026

May 09, 2026

Fulgent Genetics (NASDAQ:FLGT) Stock Passes Below Fifty Day Moving AverageHere's Why - MarketBeat

May 09, 2026

Fulgent Genetics (NASDAQ:FLGT) Stock Rating Lowered by Wall Street Zen - MarketBeat

May 09, 2026

May 08, 2026

Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm - The Globe and Mail

May 08, 2026

May 07, 2026

Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics - BioSpace

May 04, 2026

PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics - Business Wire

May 04, 2026

May 02, 2026

Fulgent Genetics, Inc. (NASDAQ:FLGT) Q1 2026 Earnings Call Transcript - Insider Monkey

May 02, 2026

Fulgent Q1 2026 slides: revenue misses amid customer loss, therapy data shines - Investing.com Nigeria

May 02, 2026

Fulgent Genetics Reports Q1 2026 Results: $71M Revenue, Stock Buyback, Updated Guidance and Progress in Cancer Therapeutics - Minichart

May 02, 2026